Samarium-153 therapy for prostate cancer: The evaluation of urine activity, staff exposure and dose rate from patients

Simple item page
dc.contributor.authorParlak Y.
dc.contributor.authorGumuser G.
dc.contributor.authorSayit E.
dc.date.accessioned2024-07-22T08:13:46Z
dc.date.available2024-07-22T08:13:46Z
dc.date.issued2015
dc.description.abstractThe aim of this study was to determine the excretion of Samarium-153-ethylenediaminetetramethylphosphonic acid (153Sm- EDTMP) in urine and to calculate the dose rate of its retention in the body as a function of time and the dose received by the skin of laboratory staff 's finger. Urine samples were collected from 11 patients after intravenous injection of 153Sm-EDTMP. The measurements of dose rate were performed. Thermoluminescent dosemeters were used for absorbed dose measurements. Effective half-lives that were calculated from urine sample measurements were found as 7.1±3 h within the first 24 h. Whole body dose rates before collecting urine of patients were 60.0 ± 15.7 μSv h21 for within 1 h following 153Sm-EDTMP administration. The highest finger radiation dose is to the right-hand thumb (3.8 ± 2 mGy). The results of the study imply that patients who recieved 153Sm-EDTMP therapy should be kept a minumum of 8 h in an isolated room at hospital and that one staff should give therapy at most two patients per week. © The Author 2014.
dc.identifier.DOI-ID10.1093/rpd/ncu237
dc.identifier.issn01448420
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16403
dc.language.isoEnglish
dc.publisherOxford University Press
dc.subjectAged
dc.subjectAnalgesics, Non-Narcotic
dc.subjectBone Neoplasms
dc.subjectHumans
dc.subjectMale
dc.subjectMetabolic Clearance Rate
dc.subjectMiddle Aged
dc.subjectOccupational Exposure
dc.subjectOrganometallic Compounds
dc.subjectOrganophosphorus Compounds
dc.subjectProstatic Neoplasms
dc.subjectRadiation Dosage
dc.subjectRadiopharmaceuticals
dc.subjectSkin
dc.subjectTissue Distribution
dc.subjectanalgesic agent
dc.subjectorganometallic compound
dc.subjectorganophosphorus compound
dc.subjectradiopharmaceutical agent
dc.subjectsamarium ethylenediaminetetramethylenephosphonate
dc.subjectaged
dc.subjectanalysis
dc.subjectBone Neoplasms
dc.subjecthuman
dc.subjectmale
dc.subjectmetabolic clearance rate
dc.subjectmetabolism
dc.subjectmiddle aged
dc.subjectoccupational exposure
dc.subjectpathology
dc.subjectProstatic Neoplasms
dc.subjectradiation dose
dc.subjectradiation response
dc.subjectsecondary
dc.subjectskin
dc.subjecttissue distribution
dc.subjecturine
dc.titleSamarium-153 therapy for prostate cancer: The evaluation of urine activity, staff exposure and dose rate from patients
dc.typeArticle

Files

Collections

Scopus Koleksiyonu